Michael (Mike) Hutton, PhD, joined Eli Lilly as chief scientific officer for neurodegenerative disease in 2009 and was promoted to his current position, vice president, neurodegeneration research, in 2018. He is now based at Lilly Research Laboratories in Indianapolis and leads Lilly’s drug discovery for Alzheimer’s Disease (AD), Parkinson’s disease and ALS. Lilly’s AD portfolio currently has eight experimental therapies in clinical development that target amyloid, tau and symptom relief. Prior to joining Lilly, Mike worked at Merck (two years) and at the Mayo Clinic Jacksonville as professor of neuroscience (11 years). During his time at the Mayo Clinic, his team played a major role in determining the causes of fronto-temporal dementia (FTD) with the discovery mutations in tau (MAPT) and progranulin (GRN) and the mechanism by which these lead to neurodegeneration. Mike received the Potamkin (2000) and Metlife (2001) Prizes for his work on AD and FTD. He has published more than 200 papers in peer-reviewed journals and is a regular speaker at international conferences on neurodegenerative conditions.